Close Menu


The deal took effect immediately and shipments have to Spain, France, Germany, and the UK have begun.

The last week has seen several COVID-19 publications from proteomics groups as the field explores what it can add to drug and diagnostics development.

In PNAS this week: interactions of coronavirus' EndoU endoribonuclease enzyme, analysis of phylogenetic trees, and more.

SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.

The international initiative will aim to produce information, tools, and policy models to help assess and prevent genetic discrimination.

The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.

The sequencing-based test is designed to detect mutations that cause resistance to 15 first- and second-line antibiotics used to treat tuberculosis.

The company's in vitro diagnostic qRT-PCR test detects viral RNA and targets three genes of the SARS-CoV-2 virus: the N, Orf1ab, and E genes.

An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.

Following its Path

The UK is launching a research consortium to sequence SARS-CoV-2 samples from patients.


A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.